Insys founder John Kapoor has maintained his innocence in the face of charges.
Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.
MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.
Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.
Accenture has taken another big step into the agency space by launching a programmatic media planning and buying unit.
Keytruda passes late-stage trial; Astellas to cut 600 jobs in restructuring; Teva expects FDA decision on migraine drug by mid-September.
Nanobiosym hired the agency shortly after its proprietary technology was approved by the FDA.
Geisinger looks to expand DNA sequencing program; Celgene invests $65 million more in Evotec; Oscar launches transparency push.
Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug prices
The White House's strategy calls for moving expensive treatments from under Medicare Part B to Medicare Part D.
The Beating Cancer Is in Our Blood brand positioning was developed with Oberland.
FDA approves AstraZeneca potassium drug; Nabriva pneumonia treatment meets Phase III endpoints; "Bad Blood" hits bookshelves.
MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.
First preventative migraine treatment approved; NIH investigates funding for alcohol study; Trump to block federal funding for abortion clinics.